The Manufacturers Life Insurance Company grew its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) by 21.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 533,745 shares of the life sciences company’s stock after acquiring an additional 94,821 shares during the period. The Manufacturers Life Insurance Company owned 0.64% of Integra LifeSciences worth $22,609,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently modified their holdings of the company. Goldman Sachs Group Inc. increased its position in Integra LifeSciences by 2.5% in the first quarter. Goldman Sachs Group Inc. now owns 1,519,743 shares of the life sciences company’s stock worth $97,658,000 after purchasing an additional 37,025 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Integra LifeSciences by 1.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,380,036 shares of the life sciences company’s stock worth $88,686,000 after buying an additional 23,877 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its stake in shares of Integra LifeSciences by 14.0% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 802,724 shares of the life sciences company’s stock worth $51,583,000 after buying an additional 98,702 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Integra LifeSciences by 3.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 658,928 shares of the life sciences company’s stock valued at $42,343,000 after acquiring an additional 23,751 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in Integra LifeSciences by 41.3% during the 2nd quarter. Millennium Management LLC now owns 457,069 shares of the life sciences company’s stock worth $24,695,000 after acquiring an additional 133,571 shares during the period. 87.60% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on IART shares. Jefferies Financial Group assumed coverage on Integra LifeSciences in a research note on Tuesday, October 11th. They issued a “hold” rating and a $48.00 price target on the stock. StockNews.com began coverage on Integra LifeSciences in a research report on Wednesday, October 12th. They set a “buy” rating for the company. TheStreet upgraded shares of Integra LifeSciences from a “c+” rating to a “b-” rating in a research report on Tuesday, December 27th. Citigroup upped their target price on shares of Integra LifeSciences from $50.00 to $60.00 and gave the company a “neutral” rating in a research note on Monday, December 12th. Finally, JMP Securities decreased their price target on shares of Integra LifeSciences from $85.00 to $75.00 and set a “market outperform” rating for the company in a report on Thursday, October 27th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $58.33.
Integra LifeSciences Stock Down 0.5 %
Integra LifeSciences (NASDAQ:IART – Get Rating) last posted its quarterly earnings results on Wednesday, October 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.14. Integra LifeSciences had a net margin of 11.05% and a return on equity of 16.41%. The firm had revenue of $385.19 million for the quarter, compared to analyst estimates of $377.79 million. Equities research analysts expect that Integra LifeSciences Holdings Co. will post 3.33 earnings per share for the current fiscal year.
About Integra LifeSciences
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company’s neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.
- Get a free copy of the StockNews.com research report on Integra LifeSciences (IART)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- Is It Time To Get Aggressive With Defense Stocks?
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.